The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

We pay — by far — the highest prices in the world, for everything from the antipsychotic Abilify to the weight loss drug Zepbound. But don’t get ... For instance, a one-month supply of Novo Nordisk’s ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Only three drugs – Novo Nordisk’s Wegovy and Saxenda, and Eli Lilly’s Zepbound – are actually approved for that purpose. Now, if used correctly, these drugs can be a lifeline for patients.

The Canadian Medical Association (CMA) congratulates Canada's Minister of Health Marjorie Michel and the entire new federal cabinet on their appointments today. The CMA is eager to collaborate with ...